Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone s...
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- -
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients
- First Posted Date
- 2020-01-30
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Wonju Severance Christian Hospital
- Target Recruit Count
- 164
- Registration Number
- NCT04248621
- Locations
- 🇰🇷
Department of Urology, Chonnam National University, School of Medicine, Gwangju, Korea, Republic of
🇰🇷Department of Urology, Kyungpook National University, School of Medicine, Daegu, Korea, Republic of
🇰🇷Department of Urology, Eulji University, College of Medicine, Daejeon, Korea, Republic of
Cardiovascular Events in GnRH Agonist vs. Antagonist
- Conditions
- Interventions
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT04182594
- Locations
- 🇮🇱
Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 208
- Registration Number
- NCT04176081
- Locations
- 🇨🇦
UHN Princess Margaret Hospital, Toronto, Ontario, Canada
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Mark Stein
- Target Recruit Count
- 20
- Registration Number
- NCT03951831
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Mark Stein
- Target Recruit Count
- 60
- Registration Number
- NCT03689699
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Cancer Center- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Conditions
- Interventions
- Drug: AbirateroneDrug: BicalutamideDrug: DegarelixDrug: FlutamideDrug: DocetaxelDrug: Goserelin AcetateDrug: Histrelin AcetateDrug: Leuprolide AcetateDrug: NilutamideProcedure: OrchiectomyOther: Quality-of-Life AssessmentRadiation: Radiation TherapyDrug: PrednisoneProcedure: Radical ProstatectomyDrug: Triptorelin
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1273
- Registration Number
- NCT03678025
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03361735
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 30
- Registration Number
- NCT03358563
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Assisting Nature
- Target Recruit Count
- 120
- Registration Number
- NCT03240159
- Locations
- 🇬🇷
Assisting Nature, Thessaloníki, Greece
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2017-06-28
- Target Recruit Count
- 35
- Registration Number
- NCT03202381
- Locations
- 🇮🇹
Clinical Department of Urology, university Hospital Spedali Civili di Brescia, Brescia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.